Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04935112 · ClinicalTrials.gov registry record · Phase 1
A Study to Explore the Effect of Acid-reducing Agents
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04935112 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT04935112, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects. The study is a single-center, open-label, 2-period, 2-treatment, fixed-sequence crossover, parallel-group study.
Interventions
- DRUG Famotidine
- DRUG Pantoprazole
- DRUG Sitravatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2022-07-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04935112
The ClinicalTrials.gov registry entry for NCT04935112 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Famotidine is the first listed.
NCT04935112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04935112 about?
NCT04935112 is a clinical study titled "A Study to Explore the Effect of Acid-reducing Agents". A Phase 1 Study of the Effect of Acid-reducing Agents on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects. The study is a single-center, open-label, 2-period, 2-treatment, fixed-sequence crossover, parallel-group study.
What is the current status of trial NCT04935112?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-07-07. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT04935112?
The interventions under investigation include: Famotidine (DRUG), Pantoprazole (DRUG), Sitravatinib (DRUG).
Who is sponsoring clinical trial NCT04935112?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.